Skip to main content

Talk Bio

Search This Blog

Incyte inks deal with Edison Scientific to train AI through drug discovery

on May 19, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Incyte partners with Edison Scientific to deploy its AI scientist Kosmos across the drug discovery and development lifecycle, using Incyte's translational and clinical data to train AI models that can improve therapeutic‑performance predictions and experimental decisions.

Initial deployment focuses on high‑impact workflows in target discovery, validation, and translational biology, with the capability set to expand across Incyte's broader R&D organization over time.

Sources:

Incyte inks deal with Edison to train AI through drug discovery

Transcript : Incyte Corporation Presents at RBC Capital Markets ...

Incyte與Edison Scientific合作，利用人工智能進行藥物研發 - 富途资讯

Announcing Our Partnership with Incyte Corporation and Kosmos for ...

All Transcripts on Incyte Corporation (INCY) - MarketScreener

We Raised $70M to Accelerate Science - Edison Scientific

Edison Scientific | The AI Platform for scientific R&D

AI-Driven Drug Discovery Summit 2026

Will Incyte (INCY) Beat Estimates Again in Its Next ...

Edison Scientific Deploys Kosmos AI Agent With Incyte To Speed ...

Why Incyte (INCY) Stock Is Nosediving - Finviz

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635 ...

Inside the AI 'scientist' Incyte will use to guide drug research

INCY Press Releases Incyte - Market Chameleon

AI scientist Artificial Intelligence Clinical Data Discover Drug Discovery Edison Scientific Incyte Kosmos predictive models R&D Target translational translational biology Validation

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Xaira Therapeutics Launches X-Cell: First AI Virtual Cell Model Testing Scaling Laws on Massive Perturbation Data

Xaira Therapeutics announced X-Cell on March 17, 2026, a 4.9-billion-parameter diffusion language model, the largest virtual cell model to date, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset with 25.6 million perturbed single-cell transcriptomes across seven diverse contexts. 1 2 X-Cell predicts cell responses to genetic perturbations, outperforming existing models by up to five-fold on metrics like Pearson delta, and generalizes zero-shot to unseen biological contexts such as iPSC-derived melanocyte progenitors and primary human CD4+ T cells. 1 2 The model follows power-law scaling dynamics similar to large language models, using a novel diffusion architecture that iteratively refines predictions. 2 Xaira, founded in 2024 with over $1 billion funding, plans to expand X-Atlas to primary cells, organoids, and in vivo perturbations, focusing on inflammatory/immunological diseases and antibody therapeutics. 1 3 A subset of the Pisces dataset and X-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC